Brokerage firm Roth Capital Reinstates its rating on Pieris Pharmaceuticals Inc(NASDAQ:PIRS). The shares have been rated Buy. The rating by Roth Capital was issued on Aug 5, 2016.
Pieris Pharmaceuticals Inc (PIRS) shares turned negative on Wednesdays trading session with the shares closing down -0.06 points or -3.49% at a volume of 82,561. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $1.76. The peak price level was also seen at $1.76 while the days lowest was $1.64. Finally the shares closed at $1.66. The 52-week high of the shares is $3.48 while the 52-week low is $1.26. According to the latest information available, the market cap of the company is $71 M.
Pieris Pharmaceuticals Inc(PIRS) last announced its earnings results on May 11, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $1.25M. Analysts had an estimated revenue of $250.00K. Earnings per share were $-0.10. Analysts had estimated an EPS of $-0.12.
Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, Stephen S. Yoder (CEO) purchased 6,000 shares at $1.68 per share price.Also, On Jun 15, 2016, Darlene M Deptula-hicks (CFO) purchased 5,000 shares at $1.66 per share price.On Jun 15, 2016, Louis Matis (SVP, Chief Development Officer) purchased 10,000 shares at $1.70 per share price, according to the Form-4 filing with the securities and exchange commission.
Pieris Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of Anticalin class of biotherapeutics for patients with diseases. The Company is focused on developing two drug candidates PRS-080 and PRS-060. PRS-080 is an Anticalin protein that binds to hepcidin a natural regulator of iron in the blood. PRS-080 has been designed to target hepcidin for the treatment of functional iron deficiency (FID) in anemic patients with chronic kidney disease (CKD) in end-stage renal disease patients requiring dialysis. PRS-060 is a drug candidate that binds to the IL-4RA receptor thereby inhibiting IL-4 and IL-13 two cytokines small proteins mediating signaling between cells within the human body which are mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. It is also developing PRS-110 in cMet-related cancer and PRS-300 series.